Seminars in Radiation Oncology
Volume 16, Issue 2 , Pages 131-135 , April 2006

Treatment of Oligometastases After Successful Immunotherapy

  • James C. Yang, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to James C. Yang, MD, Surgery Branch, National Cancer Institute, Building 10, Room 2B37, Bethesda, MD 20892.
    • ,
  • John Abad, MD
    • ,
  • Richard Sherry, MD

References 

  1. Rosenberg SA , Lotze MT , Muul LM , et al.   Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer . N Engl J Med . 1985;313:1485–1492
  2. Rosenberg SA , Yang JC , Topalian SL , et al.   Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 . JAMA . 1994;271:907–913
  3. Rosenberg SA , Yang JC , White DE , et al.   Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2 . Ann Surg . 1998;228:307–319
  4. Rosenberg SA , Kawakami Y , Robbins PF , et al.   Identification of the genes encoding cancer antigens (Implications for cancer immunotherapy) . Adv Cancer Res . 1996;70:145–177
  5. Robbins P , Wang R , Rosenberg S . Tumor antigens recognized by cytotoxic lymphocytes . In:  Sitkovsky M ,  Henkart P editor. Cytotoxic Cells (Basic Mechanisms and Medical Applications) . Philadelphia, PA: Lippincott Williams and Wilkins; 2000;p. 363–383
  6. Hanada K , Perry-Lalley DM , Ohnmacht GA , et al.   Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas . Cancer Res . 2001;61:5511–5516
  7. Overwijk WW , Theoret MR , Finkelstein SE , et al.   Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells . J Exp Med . 2003;198:569–580
  8. Moretta A , Bottino C , Vitale M , et al.   Receptors for HLA class-I molecules in human natural killer cells . Annu Rev Immunol . 1996;14:619–648
  9. Mule JJ , Shu S , Schwarz SL , et al.   Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2 . Science . 1984;225:1487–1489
  10. Restifo NP , Kawakami Y , Marincola F , et al.   Molecular mechanisms used by tumors to escape immune recognition (Immunogenetherapy and the cell biology of major histocompatibility complex class I) . J Immunother . 1993;14:182–190
  11. Jager E , Ringhoffer M , Altmannsberger M . Immunoselection in vivo (Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma) . Int J Cancer . 1997;71:142–147
  12. Sherry RM , Pass HI , Rosenberg SA , et al.   Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy . Cancer . 1992;69:1850–1855
  13. Lee DS , White DE , Hurst R , et al.   Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2 based immunotherapy . Cancer J Sci Am . 1998;4:86–93
  14. Rosenberg SA , Lotze MT , Muul LM , et al.   A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone . N Engl J Med . 1987;316:889–897
  15. Rosenberg SA , Lotze MT , Yang JC , et al.   Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients . Ann Surg . 1989;210:474–484
  16. Yang JC , Topalian SL , Schwartzentruber DJ , et al.   The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma (A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2) . Cancer . 1995;76:687–694
  17. Marincola FM , White DE , Wise AP , et al.   Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer . J Clin Oncol . 1995;13:1110–1122
  18. Yang JC , Sherry R , Steinberg SM , et al.   A randomized study of high and low-dose interleukin-2 in patients with metastatic renal cancer . J Clin Oncol . 2003;21:3127–3132
  19. Lindsey KR , Rosenberg SA , Sherry RM . Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2 . J Clin Oncol . 2000;18:1954–1959

PII: S1053-4296(05)00103-7

doi: 10.1016/j.semradonc.2005.12.008

Seminars in Radiation Oncology
Volume 16, Issue 2 , Pages 131-135 , April 2006

Article Tools

* Image Usage & Resolution